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KIR3DL2/CpG ODN Interaction Mediates Se´zary
Syndrome Malignant T Cell Apoptosis
Bouchra Ghazi1, Nicolas Thonnart1,2, Martine Bagot1,2,3, Armand Bensussan1,2,3 and Anne Marie-Cardine1,2
We previously identified the NK cell receptor KIR3DL2 as a valuable diagnostic and prognostic marker for the
detection of the tumoral T cell burden of Se´zary syndrome (SS) patients. However, the function of this receptor
on the malignant T lymphocyte population remained unexplored. We here demonstrate that engagement
of KIR3DL2 by its recently identified ligand CpG oligodeoxynucleotide (ODN) induces the internalization of
the receptor and leads to a caspase-dependent apoptosis of malignant T cells. This process of cellular death
is correlated to a dephosphorylation of the transcription factor STAT3 (signal transducer and activator of
transcription 3), which is found constitutively phosphorylated and activated in Se´zary cells. Our results indicate
that KIR3DL2 can directly promote SS malignant cell death through the use of CpG ODN.
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INTRODUCTION
Se´zary syndrome (SS) is an aggressive leukemic and erythro-
dermic variant of cutaneous T cell lymphoma characterized by
the presence of a clonal T lymphocyte population in the skin,
lymph nodes, and peripheral blood. Numerous studies have
tried to identify specific markers for an unequivocal detection of
Se´zary cells, which are currently identified on morphological
criteria as oversized cells presenting an atypical cerebriform
nucleus. However, this detection method is not entirely reliable
because cerebriform mononuclear cells can be detected in the
blood of healthy individuals and can also represent reactive or
normal CD4þ T cells exhibiting a Se´zary cell–like appearance
(Duncan and Winkelmann, 1978; van der Loo et al., 1981).
Similarly, the antigen expression abnormalities reported so far,
such as the loss of CD7, CD26, or CD3 expression (Edelman
and Meyerson, 2000; Bernengo et al., 2001; Rappl et al., 2001),
were not constantly observed for all patients, rendering the use
of multiple markers more accurate for the detection of the
circulating malignant cells (Klemke et al., 2008). We previously
reported that KIR3DL2 represents a specific cell surface marker
for the evaluation of the circulating tumoral burden and for the
follow-up of patients with SS (Bagot et al., 2001;
Poszepczynska-Guigne et al., 2004; Ortonne et al., 2006;
Bouaziz et al., 2010). KIR3DL2 is a member of the killer cell
Ig-like receptor (KIR) family, whose ligand specificity was
assigned to HLA-A3 and -A11 through a peptide–specific
interaction (Hansasuta et al., 2004) and to HLA-B27 homo-
dimer through a peptide–independent recognition (Kollnberger
et al., 2007). More recently, CpG oligodeoxynucleotides
(ODNs) were also identified as KIR3DL2 ligands on NK cells,
the interaction between CpG DNA and KIR3DL2 leading to the
endocytosis of the ligand/receptor complexes and to NK cell
activation (Sivori et al., 2010).
The specific expression of KIR3DL2 in SS patient malignant
cells prompted us to investigate its possible influence on
mechanisms regulating tumoral cell growth and apoptosis.
Cellular outcomes and signaling were analyzed following
KIR3DL2 engagement by using its recently identified ligand
CpG ODN.
RESULTS
KIR3DL2 internalization is induced in Se´zary cells upon
engagement with CpG ODN
Because CpG ODNs were shown to promote KIR3DL2 cell
surface downmodulation on NK cells (Sivori et al., 2010), we
first tested whether this observation also applied to malignant
Se´zary cells. We observed that incubation of Se´zary patients’
peripheral blood mononuclear cells (PBMCs) with type A, B,
or C CpG ODNs, but not with a control ODN, led to
a significant downmodulation of KIR3DL2, corresponding
to a 50% reduction in the receptor mean fluorescence inten-
sity (MFI), at the surface of Se´zary patients’ CD4þ T cells
(Supplementary Table S1 online). CpG ODN-C was preferen-
tially used for the following experiments because it induced
efficient cell surface modulation of KIR3DL2 and combined
the immune effects of class-A and -B ODN on immune cells
(Krieg, 2002; Vollmer et al., 2004). To definitely assess that
the expression level of KIR3DL2 was downmodulated on
malignant cells, immunolabelings including an anti-TCRVb
mAb (that identifies the tumoral T cell clone) were performed
on both the Se´zary cell line Pno and PBMCs from Se´zary
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patients whose TCRVb rearrangement of their malignant T cell
clone was identified (Figure 1a). The resulting data demon-
strated that ODN-C promoted KIR3DL2 downmodulation
on the cell line (Figure 1a, upper panel) and on the patients’
malignant circulating T cell clone, as assessed by the decrease
in receptor expression detected on the CD3þCD4þVbþ
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Figure 1. Downmodulation of KIR3DL2 expression on tumoral Se´zary T-cell clone upon CpG ODN-C treatment. (a) The Se´zary cell line (Pno) or PBMCs
from Se´zary patients were left untreated (NT) or incubated in the presence of CpG ODN-C or control ODN (10mg ml1) for 8 or 48 hours, respectively. Cells were
labeled with anti-KIR3DL2 mAb (Q66) plus FITC-conjugated goat anti-mouse IgM secondary antibodies, anti-TCRVb-PE, -CD3-PC5, and CD4-PC7 mAbs. TCRVb/
KIR3DL2 staining corresponding to the gated CD3þCD4þ T lymphocyte population is shown. The mean fluorescence intensity (MFI) of KIR3DL2 labeling is
indicated. (b) Graphical representation of KIR3DL2 MFI observed on the CD3þCD4þ T cells from Se´zary patients (n¼ 12), following incubation in medium alone
(NT) or supplemented with CpG ODN-C or control ODN. *P¼ 0.004 compared with NT condition. ODN, oligodeoxynucleotide; PBMCs, peripheral blood
mononuclear cells.
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T cell population (Figure 1a, patients one, two, and four). Such
significant decrease in KIR3DL2 surface expression upon
ODN-C treatment was obtained in samples from 12 different
Se´zary patients tested (Figure 1b; Po0.005).
To directly visualize KIR3DL2 cellular location together
with ODN-C, fluorescence microscopy analyses were per-
formed. LAMP-1 was used as a marker for the endosomes/
lysosomes compartments (Ebrahim and Thilo, 2011). In resting
cells, KIR3DL2 was mainly detected at the plasma membrane
(Figure 2a, upper panel). Similarly, FITC-conjugated ODN-C
labeling of untreated cells led to the detection of a membrane–
bound signal (Figure 2a, lower panel). After treatment with
control ODN, no major relocation of KIR3DL2 was detected
(Figure 2b). In contrast, incubation of the cells with ODN-C
led to a complete redistribution of KIR3DL2 that became
detected in the LAMP-1 endo-lysosomal compartment
(Figure 2c). The use of FITC-conjugated ODN-C allowed the
detection of its co-internalization with KIR3DL2 (Figure 2d,
upper panel) and its presence within the LAMP-1–positive
intracellular compartment (Figure 2d, lower panel). Together,
these data showed that binding of CpG ODN-C to KIR3DL2
promotes internalization of the receptor/ODN complexes in
Se´zary cells, similarly to what was reported in peripheral
blood NK lymphocytes (Sivori et al., 2010).
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Figure 2. Internalization of KIR3DL2 following ODN-C treatment. Cells were left untreated (a) or incubated 6 hours in the presence of control ODN (b), ODN-C
(c), or FITC-conjugated ODN-C (d). Immunolabelings were then performed using FITC–coupled ODN-C, anti-LAMP1, and/or anti-KIR3DL2 antibodies, as
indicated. Scale bar¼10mm. ODN, oligodeoxynucleotide.
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CpG ODN-C/KIR3DL2 interaction leads to Se´zary cell apoptosis
To further investigate the consequences of KIR3DL2 triggering
by CpG ODN-C in Se´zary cells, we evaluated its role in the
process of malignant T cell survival. Experiments performed
on the Pno Se´zary cell line highlighted a deleterious function
for CpG ODN-C, with the detection of B60% of apoptotic
cells after 24 hours of treatment, whereas control ODN
showed no effect on the cell line survival (Figure 3a). When
similar experiments were performed on PBMCs from Se´zary
patients, no malignant cell death was detected in the presence
of ODN-C at this time point (data not shown). Incubation time
with CpG ODN-C or control ODN was therefore extended up
to 12 days. Note that only patients showing a high tumoral
burden and over 98% of KIR3DL2þ cells within their CD4þ T
lymphocyte population were selected for these experiments,
as exemplified with patient 15 (Supplementary Figure S1
online). Representative results obtained on PBMCs from
patient 15 at days 3, 7, and 10 are shown in Figure 3b.
Despite the detection of an increased spontaneous cell death
during the time course, as assessed by both 7AAD labeling
and cell count (see Figure 3b, NT panels and Supplementary
Figure S2 online), addition of ODN-C resulted in a significant
increase in the percentage of malignant (Vb3þ ) cells that
underwent apoptosis on days 7 and 10. In contrast, control
ODN treatment did not modify the rate of cell death when
compared with untreated cells. Furthermore, the survival of
the non-tumoral cell populations (Vb3 cells) was not affec-
ted upon ODN-C treatment, with similar levels of Vb3
7AADþ cells being detected under all conditions of incuba-
tion and at all time points. Experiments performed on PBMCs
isolated from healthy donors (n¼4) revealed that normal
CD4þ T cell viability was not affected by the presence of
ODN-C (Supplementary Figure S3 online). Similar results were
obtained on cells from eight patients (Figure 3c), with maximal
ODN-C–induced apoptosis detected after 7–12 days of treat-
ment depending on the patient.
CpG ODN-C treatment of Se´zary cells results in caspase
activation and phospho-STAT3 dephosphorylation
The induction of a caspase–dependent apoptotic pathway
following incubation with ODN-C was investigated by immuno-
blotting on the Pno Se´zary cell line and on CD4þ T cells
isolated from patients (n¼3) whose CD4þ T cell population
was identified as entirely tumoral by performing TCRVb/
KIR3DL2 immunolabeling (Supplementary Figure S4 online).
The obtained results showed that the levels of cleaved forms of
caspase-7 and -3, and of their substrate PARP, were increased
after incubation of both cell types with CpG ODN-C when
compared with untreated cells (Figure 4). However, maximal
activation of the caspase pathway was achieved after 24 hours
of treatment for the Se´zary cell line but required over 7 days
for the patients’ malignant cells, these delays of response being
in agreement with the apoptosis data obtained by flow cyto-
metry (see Figure 3). Together, these results showed that specific
apoptosis of Se´zary malignant cells is induced by CpG ODN-C
treatment through a caspase-dependent pathway.
Previous studies have established that signal transducer
and activator of transcription 3 (STAT3) can be constitutively
phosphorylated in Se´zary cells and that treatments promoting
its dephosphorylation lead to malignant cell death (Eriksen
et al., 2001; van Kester et al., 2008; Zhang et al., 2010). We
therefore investigated the phosphorylation status of STAT3 in
CpG ODN-C–treated cells. Experiments performed on the Pno
cell line or purified CD4þ T cells of three patients (whose
CD4þ T lymphocytes were all KIR3DL2þ ; Supplementary
Figure S4 online) showed that a complete STAT3 dephos-
phorylation, which is not correlated to the degradation of the
protein, occurred upon ODN-C treatment, whereas the
phospho-STAT3 level was not modified in the presence of
control ODN (Figure 5). Again, a much faster effect of ODN-C
was seen in the Pno cell line when compared with Se´zary
patients’ cells. Thus, the STAT3 dephosphorylation process
was mainly completed after 8 hours of treatment in the Pno
cell line, whereas it required 3 days for the patients’ circulat-
ing malignant cells. Nevertheless, these data demonstrated
that the CpG ODN-C–induced apoptosis of Se´zary cells might
be correlated to STAT3 dephosphorylation.
DISCUSSION
Advanced stages of SS are associated with aggressive tumors
and poor prognosis. In this context, one critical issue was to
identify a specific marker of Se´zary cells allowing a reduction
in diagnosis time and the unequivocal targeting of the
circulating tumoral cells. We previously identified KIR3DL2
as a reliable marker of both skin-homing and peripheral blood
malignant T cells (Bagot et al., 2001; Poszepczynska-Guigne
et al., 2004). Because of its primary amino acid sequence,
KIR3DL2 has an inhibitory role in NK and in cytotoxic CD8þ
T cells. Moreover, KIR3DL2 expression has been reported
in tumor-specific cytotoxic T cell clones isolated from
T lymphocytes infiltrating human lung carcinoma, but its
engagement did not result in an inhibition of cytotoxicity or
cytokine release (Dorothee et al., 2003). We now demonstrate
that KIR3DL2 engagement by its recently identified ligand
CpG ODN promotes the internalization of the receptor and
the generation of apoptotic signals in Se´zary cells.
For all patients’ samples tested, we experienced on average
a 50% reduction in KIR3DL2 MFI following CpG ODN
treatment. This reduction did not increase with higher con-
centrations of CpG ODN (up to 25 mg ml1) or a longer
exposure time (up to 12 days) (data not shown). In NK cells,
KIR3DL2 internalization leads to the co-localization of CpG
ODN-linked receptors with Toll-like receptor 9 (TLR9) in the
endosomal compartment (Sivori et al., 2010). It has therefore
been suggested that, in these cells, KIR3DL2 may act as a
carrier protein that brings CpG ODN to its receptor TLR9,
resulting in NK cell activation. Despite the detection of TLR9
transcripts in Se´zary cell lines and Se´zary patient tumoral
cells, we did not detect any TLR9 expression in these cells
(data not shown). In addition, it has been reported that CpG
and non-CpG ODN can co-stimulate mouse and human
CD4þ T cells via a TLR9- and MyD88-independent mecha-
nism (Landrigan et al., 2011). Together, these data suggest the
possibility of a KIR3DL2/CpG ODN-mediated effect with no
TLR9 involvement in Se´zary cells. This also points toward
a distinct role for KIR3DL2 as a CpG ODN receptor in NK and
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Figure 3. CpG ODN-C induces malignant Se´zary cell apoptosis. (a) The Pno Se´zary cell line was left untreated (NT) or incubated with CpG ODN-C or
control ODN for 24 hours at 37 1C. Apoptotic cells were detected by 7AAD labeling. Mean±SD of four independent experiments is shown. (b) Se´zary
patient PBMCs were incubated with CpG ODN-C or control ODN at 37 1C. Immunolabeling was performed after 3, 7, or 10 days of incubation using
anti-TCRVb3-PE and -CD4-FITC mAb and 7AAD. (c) Graphical representation of the percentage of 7AAD–positive cells within the TCRVbþCD4þ population
of Se´zary patients (n¼ 8) after 7 days of incubation with CpG ODN-C (black) or control ODN (gray). *P¼ 0.006. ODN, oligodeoxynucleotide; PBMCs, peripheral
blood mononuclear cells.
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Se´zary cells (activating receptor vs. apoptosis–mediating
receptor, respectively), depending on TLR9 expression.
An alternative to overcome the lack of TLR9 in Se´zary cells
could be the involvement of cytosolic DNA receptors such as
the cytosolic GMP-AMP synthase or absent in melanoma-2
(AIM2) following KIR3DL2/ODN-C internalization. However,
an interaction between cytosolic GMP-AMP synthase and
CpG ODN-C seems unlikely as cytosolic GMP-AMP synthase
showed no or low affinity for double–stranded DNA ligand
shorter than 15 base pairs or encompassing a phosphorothioate
backbone (Karayel et al., 2009; Kranzusch et al., 2013), both
features that are shared by ODN-C. In contrast, AIM2 is
a member of the IFN-inducible HIN-200 family, whose
DNA-binding specificity allows double–stranded DNA with a
phosphorothioate backbone as ligand (Burckstummer et al.,
2009). It has been shown that the interaction of AIM2 with
double–stranded DNA led to its association with the
apoptosis–associated speck–like protein containing a CARD,
resulting in caspase-1 activation and pyroptotic cell death
(Fernandes-Alnemri et al., 2009). Although our results rather
suggest that KIR3DL2/CpG ODN-mediated cell death occurs
through a classical apoptotic pathway involving caspases 3 and
7, the possibility of AIM2 expression upon ODN-C treatment
of Se´zary cells was investigated. Experiments performed on the
KIR3DL2þ Se´zary cell line HUT78 showed no induction of
AIM2 expression upon ODN-C treatment despite effective cell
apoptosis (data not shown), excluding the participation of
AIM2 in the KIR3DL2/CpG ODN-dependent pathway.
Several studies aimed to induce Se´zary cell apoptosis
mainly through the use of drugs directed against targeted
proteins (e.g., HDAC, Janus kinase (JAK) or g-secretase
inhibitors) (Eriksen et al., 2001; van Kester et al., 2008; van
der Fits et al., 2012). Such inhibitors have proved their efficacy
in inducing Se´zary cell apoptosis in vitro, with the detection
of 20–100% of dead cells after 48 hours of treatment at the
highest concentration tested, with a usually better response
for cell lines than for patients’ circulating cells. Experiments
performed on the proliferating Se´zary cell line Pno (and
HUT78; data not shown) evidenced an internalization of
the receptor 6–8 hours after addition of the CpG ODN with
STAT3 dephosphorylation and cell apoptosis readily detected
after 24 hours. By comparison, the delay observed for detect-
ing an ODN-C/KIR3DL2–mediated apoptosis of the patients’
tumoral clone seems unusual. Indeed, despite maximal
but partial internalization of KIR3DL2 at 24–48 hours after
exposure to ODN-C, and STAT3 complete dephosphory-
lation after 3 days of treatment, detection of the patients’
circulating tumoral T cell clone apoptosis required 7–12 days
of treatment. Further studies will be needed to determine
whether these time-course discrepancies might be the con-
sequence of the low metabolic turnover of peripheral blood
tumoral cells compared with an established and proliferating
Se´zary cell line, and the need for days to shut down phos-
pho-STAT3-dependent anti-apoptotic pathways. It has been
reported that the constitutive activation of STAT3 in cutaneous
T cell lymphoma cell lines led to a constitutive expression
of SOCS3 (Brender et al., 2001). However, we did not observe
a diminished or abolished expression of SOCS3 upon ODN-C
treatment of Se´zary cells at time points at which STAT3
inactivation was readily detected (data not shown). One
can therefore wonder whether an above normal protein
stability could be a hallmark of patients’ malignant T cells.
Efforts will be made to further determine the consequences
of the ODN-C/KIR3DL2 internalization in terms of intra-
cellular molecular events to understand the precise time line
that leads to delayed STAT3 dephosphorylation and Se´zary
cell death. In this regard, previous studies demonstrated that
treatment of Se´zary cells with the JAK inhibitor tyrphostin
AG490, as well as with Cucurbitacin I or Curcumin, efficiently
promotes phospho-STAT3 dephosphorylation and induces
Se´zary cell apoptosis (Eriksen et al., 2001; Krejsgaard et al.,
2006; van Kester et al., 2008; Zhang et al., 2010). It has been
recently established that constitutive activation of STAT3 in
Se´zary cells is not due to a loss of SHP-1 but is mediated by
a constitutive aberrant activation of JAK family members
(McKenzie et al., 2011). Work is in progress to determine
whether CpG ODN binding to KIR3DL2 in Se´zary cells may
influence JAK activity.
Phase I/II trials using TLR9 agonists alone or combined with
localized low-dose radiotherapy have been conducted on
MF and SS patients (Kim et al., 2010, 2012). In both studies,
class-B CpG ODN was injected subcutaneously and led to a
clinical response rate of 32–36% with no major cytotoxic side
effects. Moreover, whereas CpG ODN induced lesion clear-
ing, significantly decreased CD25þ FoxP3þ regulatory T cells
and S100þ antigen-presenting cells, and increased levels of
CD123þ plasmacytoid dendritic cells at the sites of injection,
its effects on the circulating tumoral burden of SS patients
were not explored. Our data suggest that, as well as promoting
the generation of an anti-tumoral immune response, CpG
ODN might also initiate a direct effect on Se´zary cells by
binding to KIR3DL2.
MATERIALS AND METHODS
Patients and cells
SS diagnosis was established on recognized international clinical,
histological, and biological criteria. After obtaining written informed
patient consent, blood from 15 SS patients with more than 90% of
CD3þCD4þKIR3DL2þ cells was collected for this study, which was
approved by the institutional ethics committee (Saint Louis Hospital,
Paris). PBMCs were isolated from heparinized venous blood by density
gradient centrifugation over lymphocytes separating medium (LSM;
PAA Laboratories, Les Mureaux, France). CD4þ T cells were purified
from freshly isolated PBMCs by magnetic activated cell sorting using
the CD4þ T cell isolation kit according to the manufacturer’s protocol
(Miltenyi Biotech, Paris, France) and immediately subjected to CpG
ODN treatment (see below). The IL2-dependent Se´zary cell line (Pno)
used in this study was established and amplified as described pre-
viously, and maintained its phenotype (Poszepczynska et al., 2000).
Cells were cultured in RPMI-1640 supplemented with 2 mM
L-glutamine, 1% penicillin–streptomycin (Invitrogen, Saint Aubin,
France) and 10% human serum (Jacques Boy Biotechnologies Institute).
CpG ODN cell treatment
Cells were cultured for the indicated time in 24-well plates at a
concentration of 2 106 per ml. The following CpG ODNs were used
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at a final concentration of 10mg ml 1: class-A (ODN 2336), class-B
(ODN 2006), class-C (ODN 2395), and control ODN (ODN
TTAGGG) (all from Invivogen, Toulouse, France). Cells were incu-
bated for up to 12 days. After incubation, cells were processed for
flow cytometry or biochemical analysis, as described below. Where
indicated, cell viability was assessed by Trypan blue exclusion.
Flow cytometry
Se´zary cell staining was performed according to a standard procedure
using the anti-KIR3DL2 mAb Q66 (IgM; kindly provided by
Dr A Moretta, Genova, Italy) plus goat anti-mouse IgM-FITC (or
-PE) Abs, anti-CD3-PC7, -TCRVb-FITC (or -PE), and -CD4-PC5 mAbs
(Beckman Coulter, Marseille, France). Detection of apoptotic cells
was performed using 7AAD (BD Biosciences, Le Pont de Claix,
France), according to the supplier’s protocol. Cells were analyzed on
an FC500 cytometer (Beckman Coulter) and data analyzed with the
FlowJo software.
Immunofluorescence
Cells were either left untreated or incubated in the presence of CpG
ODN-C, FITC-labeled CpG ODN-C, or control ODN at 37 1C. Cells
were then washed and immobilized on poly-L-lysine-coated cover-
slips. After a methanol fixation step at  20 1C and permeabilization
in phosphate-buffered saline/0.1% Tween-20, anti-KIR3DL2 (Q66,
mouse IgM), -LAMP-1 (rabbit IgG, Millipore, Molsheim, France),
or/and FITC-ODN-C were added and revealed with the appropriate
Alexa488– or Texas Red–coupled secondary antibodies. After washes,
coverslips were mounted in DAPI Fluoromount-G (Southern Biotech/
Clinisciences, Nanterre, France) and analyzed on a Leica DMRB
microscope (Le Pecq, France).
Immunoprecipitation and western blotting
Untreated or ODN-treated cells were lysed, and post-nuclear super-
natants were prepared and processed as described elsewhere
(Bensussan et al., 2011). For western blotting, samples were
separated by SDS-PAGE and transferred onto a nitrocellulose
membrane. Analyses were performed using antibodies specific for
the following molecules: cleaved-caspase 3, -caspase 7, and -PARP,
phospho-STAT3, STAT3, and Erk1/2 (all from Cell Signaling
Technology/Ozyme, Saint Quentin en Yvelines, France). When
performing detection in series, a stripping procedure between
each revelation step was carried out. After incubation with the
appropriate horseradish peroxidase–conjugated secondary antibodies
(Jackson Immunoresearch/Beckman Coulter), detection was per-
formed using an ECL system (Perbio Science, Bre´bie`res, France) and
an ImageQuant LAS 400 system (GE Healthcare, Ve´lizy-Villacoublay,
France).
Statistical analysis
Statistical analyses were performed using Student’s t test (one tailed,
paired). The given P-values for each condition correspond to the
comparison with untreated controls. For immunoblots, protein band
intensity was quantified using the Image Quant TL software (GE
Healthcare). Data were then expressed as fold-changes in treated
samples as compared with non-treated controls.
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